IL1RL1 and Alzheimer disease: However, itepekimab (another anti-IL-33 monoclonal antibody) and astegolimab (anti-IL-33R monoclonal antibody), have recently shown not result in meaningful improvements in eczema area and severity index (EASI) scores versus placebo in a phase II clinical trial for moderate-severe AD patients (170).